JUBLPHARMABSEJUBILANT PHARMOVA LTD· Pharmaceuticals & BiotechnologyHighNegative
Announced Tue, 1 Sept, 2026 · 12:42 IST

GST Show Cause Notice from Mysore Tax Authority for FY 2022-23

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.7%Reaction day
₹887.00
prior close
₹893.85
announcement price
In-mkt
timing
Nifty Smallcap 250market-0.0%+1.7% vs market
Pharmaceuticals peers, median of 175sector-0.3%+2.0% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Smallcap 250 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.1
10m
+0.3
15m
+0.2
30m
+0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.7-0.0+1.7-0.3+2.0
Next day
+1.5-0.6+2.1-0.5+2.0
2d
+2.5+0.4+2.1+0.0+2.5
3d
+4.5+0.6+3.9+0.2+4.3
4d
+7.2+0.6+6.6+0.2+7.0
5d
+12.7+0.8+11.9+0.8+11.9
1w
+15.7+0.3+15.3+0.3+15.4
15d
+19.7+0.2+19.5+0.7+19.0
1m
+12.7-4.3+17.0-1.3+14.1
2m
—————
3m
—————
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 175Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jubilant Pharmova received a GST Show Cause Notice from the Assistant Commissioner of Commercial Taxes, Mysore for FY 2022-23. The notice alleges ineligible ITC, excess ITC availed, and differential tax liability based on E-waybill records. Total demand: Tax Rs 33.58 Cr plus Interest Rs 20.15 Cr plus Penalty Rs 33.58 Cr, totalling Rs 87.31 Cr. The company calls the notice factually and legally incorrect and plans to file a detailed reply. It expects no financial or operational impact.

Likely market impact

A contested GST demand of Rs 87.31 Cr; company expects no material impact as it plans to contest with a strong case.